Literature DB >> 23606133

Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks.

Srdjan Ljubisavljevic1, Ivana Stojanovic, Slobodan Vojinovic, Maja Milojkovic, Olivera Dunjic, Dragan Stojanov, Dusica Pavlovic.   

Abstract

In order to examine the endogenous antioxidants values in the earliest phase of demyelination, we have determined bilirubin and uric acid (UA) serum values in the patients with clinically isolated syndrome (CIS) and relapsing remitting multiple sclerosis (RRMS), regarding their clinical disability, measured by Extended Disability Status Scale (EDSS), Magnetic Resonance Imaging (MRI), disease duration, gender and other parameters. The bilirubin and UA levels were lower in CIS and RRMS patients than in control group, whether male or female (p < 0.05). The bilirubin and UA levels were decreased in RRMS compared to CIS patients (p < 0.05). Regarding EDSS, MRI and disease duration, obtained values of bilirubin and UA were higher in both study groups in patients with lower EDSS, lower MRI lesion number and shorter disease duration (p < 0.05). The greatest significance in decreased bilirubin and UA levels was observed in female compared to male patients, in both study groups (p < 0.05). The results suggest negative linear correlation between bilirubin and UA levels and disease duration, EDSS and MRI in CIS (p < 0.01), with the same correlation between bilirubin and UA levels and disease duration in RRMS patients (p < 0.01). There was also significant correlation between bilirubin level and MRI findings and UA levels and EDSS in RRMS patients (p < 0.01). The obtained results point to the importance of endogenous antioxidants in the outbreak and course of neuroinflammation. This could be favorable for the new pathogenetically conditioned neuroinflammatory therapy concepts which do not initially rely only on immunomodulatory, but also on the antioxidative effects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23606133     DOI: 10.1007/s11011-013-9409-z

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  42 in total

Review 1.  Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?

Authors:  R E Gonsette
Journal:  Mult Scler       Date:  2007-09-19       Impact factor: 6.312

2.  Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis.

Authors:  D C Hooper; G S Scott; A Zborek; T Mikheeva; R B Kean; H Koprowski; S V Spitsin
Journal:  FASEB J       Date:  2000-04       Impact factor: 5.191

3.  Heme oxygenase-2 protects against glutathione depletion-induced neuronal apoptosis mediated by bilirubin and cyclic GMP.

Authors:  Jijun Chen; Yajun Tu; Erin C Connolly; Gabriele V Ronnett
Journal:  Curr Neurovasc Res       Date:  2005-04       Impact factor: 1.990

4.  Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis.

Authors:  G S M Ramsaransing; D J Heersema; J De Keyser
Journal:  Eur J Neurol       Date:  2005-07       Impact factor: 6.089

5.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

6.  The role of uric acid in protection against peroxynitrite-mediated pathology.

Authors:  G S Scott; D C Hooper
Journal:  Med Hypotheses       Date:  2001-01       Impact factor: 1.538

7.  Heme oxygenase-1 and NADPH cytochrome P450 reductase expression in experimental allergic encephalomyelitis: an expanded view of the stress response.

Authors:  M R Emerson; S M LeVine
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

8.  Uric acid levels in sera from patients with multiple sclerosis.

Authors:  J Drulović; I Dujmović; N Stojsavljević; S Mesaros; S Andjelković; D Miljković; V Perić; G Dragutinović; J Marinković; Z Lević; M Mostarica Stojković
Journal:  J Neurol       Date:  2001-02       Impact factor: 4.849

9.  Serum uric acid and multiple sclerosis.

Authors:  S Sotgiu; M Pugliatti; A Sanna; A Sotgiu; M L Fois; G Arru; G Rosati
Journal:  Neurol Sci       Date:  2002-10       Impact factor: 3.307

10.  Bilirubin and glutathione have complementary antioxidant and cytoprotective roles.

Authors:  Thomas W Sedlak; Masoumeh Saleh; Daniel S Higginson; Bindu D Paul; Krishna R Juluri; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-13       Impact factor: 11.205

View more
  5 in total

1.  Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy.

Authors:  Bingman Liu; Liangyu Zhao; Qingqing Yang; Dongqing Zha; Xiaoyun Si
Journal:  Int Urol Nephrol       Date:  2021-04-24       Impact factor: 2.370

2.  Predicting disease activity in patients with multiple sclerosis: An explainable machine-learning approach in the Mavenclad trials.

Authors:  Sreetama Basu; Alain Munafo; Ali-Frederic Ben-Amor; Sanjeev Roy; Pascal Girard; Nadia Terranova
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-05-09

3.  Low Antioxidant Status of Serum Uric Acid, Bilirubin, Albumin, and Creatinine in Patients With Benign Paroxysmal Positional Vertigo.

Authors:  Ke-Hang Xie; Ling-Ling Liu; Chu-Yin Su; Xiao-Feng Huang; Bao-Xing Wu; Run-Ni Liu; Hua Li; Qing-Qing Chen; Jia-Sheng He; Yong-Kun Ruan
Journal:  Front Neurol       Date:  2020-11-20       Impact factor: 4.003

4.  Evaluation of simple antioxidant blood parameters in patients with migraine.

Authors:  Zhenzhen Yang; Pengfei Xu; Chaofan Geng; Hongju Zhang
Journal:  Front Neurol       Date:  2022-07-26       Impact factor: 4.086

5.  The Impact of Multiple Sclerosis Disease Status and Subtype on Hematological Profile.

Authors:  Jacob M Miller; Jeremy T Beales; Matthew D Montierth; Farren B Briggs; Scott F Frodsham; Mary Feller Davis
Journal:  Int J Environ Res Public Health       Date:  2021-03-23       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.